The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.
Search results for: microscopic polyangiitis
The State of Clinical Research in Vasculitis: 2021
It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…
FDA Provides 2020 Rheumatology Drug Update
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
Researchers Seek ANCA-Associated Vasculitis Subtype Markers
New research on complement activation in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis underscores its important role in the pathoÂgenesis of this disease, an autoimmune condition defined by inflammation of small- and medium-caliber blood vessels.1 ANCA testing is commonly performed to help diagnose granulomatosis with polyangiitis and microscopic polyangiitis, both of which are forms of ANCA-associated…
Rheum After 5: Dr. Eric Matteson Writes Rheumatic Disease History
Over the past 20 years, Eric L. Matteson, MD, MPH, emeritus chair, Division of Rheumatology, and emeritus professor of medicine at the Mayo Clinic College of Medicine and Science, Rochester, Minn., as well as a past president of the Rheumatology Research Foundation, has authored or co-authored six books about the history of rheumatic disease and…
Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis
NEW YORK (Reuters Health)—Long-term rituximab use lowers the chance of relapse of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), compared with standard maintenance therapy, according to a report from the MAINRITSAN3 randomized trial. “Physicians should consider AAV to be a long-lasting, chronic disease which requires maintenance therapy,” says Dr. Pierre Charles of Cochin Hospital, Paris…
ANCA-Associated Vasculitis Trial Results May Change Standard of Care
SNOWMASS VILLAGE, COLO.—The study of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is ongoing, and research results should help improve treatment for this patient popÂulation. Key trials and therapeutic options were discussed at the 2020 ACR Winter Symposium during the session, Update on the Treatment of ANCA-Associated Vasculitis, by Peter A. Merkel, MD, MPH, chief of…
FDA Update: New Drug Approvals, New & Expanded Indications, & More
ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…
FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns
Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »